Ngl Fine-Chem Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021
June 01, 2021 at 06:55 pm IST
Share
NGL Fine-Chem Limited announced earnings results for the fourth quarter ended March 31, 2021. For the fourth quarter, the company announced total revenue was INR 740.696 million compared to INR 362.729 million a year ago. Net income was INR 138.392 million compared to net loss of INR 1.991 million a year ago. Basic earnings per share from continuing operations was INR 22.4 compared to basic loss per share from continuing operations of INR 0.32 a year ago. For the full year, total revenue was INR 2,659.923 million compared to INR 1,547.372 million a year ago. Net income was INR 567.189 million compared to INR 83.353 million a year ago. Basic earnings per share from continuing operations was INR 91.81 compared to INR 13.49 a year ago.
NGL Fine-Chem Limited is an India-based company, which is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health. The Company caters to various global companies to custom manufacture pharmaceuticals. Its products include APIs Animal Health, APIs Human Health, Intermediates and Specialty Chemicals and Finished Dosage Form. The APIs Animal Health products include Homidium Chloride, Nitroxynil, Clorsulon, Parvaquone, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Butaphosphan, Imidocarb Dipropionate, Triclabendazole, Rafoxanide, Diminazene Aceturate, S-Methoprene, Carprofen and others. The APIs Human Health products include Nitazoxanide and Atovaquone. The Intermediates and Specialty Chemicals product includes 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-Ethyl Glucamine. The Finished Dosage Form products include Diminazene Aceturate Granules and Homidium Chloride Tablets. It has manufacturing plants located around Mumbai.
NGL FINE-CHEM LIMITED 
